Senseonics Holdings, Inc. Common Stock Q4 2024 Earnings Report

Senseonics Holdings, Inc. Common Stock EPS Results

• Actual EPS: -$2.40
• Consensus EPS: -$0.60
• Beat/Miss: Missed by -$1.80
• One Year Ago EPS: -$1.40

Senseonics Holdings, Inc. Common Stock Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Senseonics Holdings, Inc. Common Stock Announcement Details

• Quarter: Q4 2024
• Date: 3/3/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Senseonics Holdings, Inc. develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal. The company has pursued regulatory approvals and commercial rollouts in multiple geographies, including the United States and Europe, and has worked with distributors and clinical partners to make its system available to patients and diabetes care teams. Its offerings are intended to integrate with diabetes management workflows by providing real-time glucose data, trends and alerts to patients and clinicians.

In addition to commercializing its implanted CGM technology, Senseonics continues to focus on product development, clinical evidence generation and expanding access through partnerships with healthcare providers and distributors. As a publicly traded company, Senseonics reports on its progress through regulatory filings and corporate disclosures; prospective investors and patients should review the company’s official materials for the latest information on regulatory status, availability and leadership.